{"id":"https://openalex.org/W2017505271","doi":"https://doi.org/10.1517/14740331003623218","title":"Pioglitazone: side effect and safety profile","display_name":"Pioglitazone: side effect and safety profile","alternate_titles":[],"publication_year":2010,"publication_date":"2010-02-23","ids":{"openalex":"https://openalex.org/W2017505271","doi":"https://doi.org/10.1517/14740331003623218","mag":"2017505271","pmid":"https://pubmed.ncbi.nlm.nih.gov/20175701"},"language":"en","primary_location":{"id":"doi:10.1517/14740331003623218","doi":"https://doi.org/10.1517/14740331003623218","is_oa":false,"landing_page_url":"https://doi.org/10.1517/14740331003623218","pdf_url":null,"source":{"id":"https://openalex.org/S20709540","display_name":"Expert Opinion on Drug Safety","issn_l":"1474-0338","issn":["1474-0338","1744-764X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Drug Safety","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2017505271"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5109990238","display_name":"Priya Shah","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Priya Shah","raw_affiliation_strings":["University of California at San Diego, Department of Medicine, 3350 La Jolla Village Drive (Mail Code: 111 G), San Diego, CA 92161, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of California at San Diego, Department of Medicine, 3350 La Jolla Village Drive (Mail Code: 111 G), San Diego, CA 92161, USA","institution_ids":["https://openalex.org/I36258959"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5089649262","display_name":"Sunder Raj D. Mudaliar","orcid":"https://orcid.org/0000-0003-4441-8508","observed_orcids":["https://orcid.org/0000-0003-4441-8508"]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4210099595","display_name":"VA San Diego Healthcare System","ror":"https://ror.org/00znqwq11","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1322918889","https://openalex.org/I2799886695","https://openalex.org/I4210099595","https://openalex.org/I4210138663"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sunder Mudaliar","raw_affiliation_strings":["Diabetes/Metabolism Section, VA San Diego HealthCare System, Associate Clinical Professor of Medicine, University of California at San Diego, Department of Medicine, 3350 La Jolla Village Drive (Mail Code: 111 G), San Diego, CA 92161, USA ; ;","Diabetes/Metabolism Section, VA San Diego HealthCare System, Associate Clinical Professor of Medicine, University of California at San Diego, Department of Medicine, 3350 La Jolla Village Drive (Mail Code: 111 G), San Diego, CA 92161, USA +1 858 552 8585 ext. 3152"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Diabetes/Metabolism Section, VA San Diego HealthCare System, Associate Clinical Professor of Medicine, University of California at San Diego, Department of Medicine, 3350 La Jolla Village Drive (Mail Code: 111 G), San Diego, CA 92161, USA ; ;","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4210099595"]},{"raw_affiliation_string":"Diabetes/Metabolism Section, VA San Diego HealthCare System, Associate Clinical Professor of Medicine, University of California at San Diego, Department of Medicine, 3350 La Jolla Village Drive (Mail Code: 111 G), San Diego, CA 92161, USA +1 858 552 8585 ext. 3152","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4210099595"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":2.1672,"has_fulltext":false,"cited_by_count":238,"citation_normalized_percentile":{"value":0.89104278,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":99,"max":100},"biblio":{"volume":"9","issue":"2","first_page":"347","last_page":"354"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9746000170707703,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9746000170707703,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11072","display_name":"Peroxisome Proliferator-Activated Receptors","score":0.0203000009059906,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10027","display_name":"Diabetes, Cardiovascular Risks, and Lipoproteins","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pioglitazone","display_name":"pioglitazone","score":1.0},{"id":"https://openalex.org/keywords/thiazolidinediones","display_name":"thiazolidinediones","score":0.9990000128746033},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9639999866485596},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.7799999713897705},{"id":"https://openalex.org/keywords/adverse-effects","display_name":"adverse effects","score":0.8709999918937683},{"id":"https://openalex.org/keywords/cardiovascular-risk","display_name":"cardiovascular risk","score":0.8159999847412109},{"id":"https://openalex.org/keywords/ppargamma","display_name":"PPAR\u03b3","score":0.8519999980926514},{"id":"https://openalex.org/keywords/insulin-resistance","display_name":"insulin resistance","score":0.7300000190734863},{"id":"https://openalex.org/keywords/weight-gain","display_name":"weight gain","score":0.6919999718666077},{"id":"https://openalex.org/keywords/pedal-edema","display_name":"pedal edema","score":0.9100000262260437},{"id":"https://openalex.org/keywords/bone-loss","display_name":"bone loss","score":0.9779999852180481},{"id":"https://openalex.org/keywords/congestive-heart-failure","display_name":"congestive heart failure","score":0.9850000143051147},{"id":"https://openalex.org/keywords/troglitazone","display_name":"troglitazone","score":0.7540000081062317},{"id":"https://openalex.org/keywords/rosiglitazone","display_name":"rosiglitazone","score":0.9120000004768372},{"id":"https://openalex.org/keywords/all-cause-mortality","display_name":"all-cause mortality","score":0.6700000166893005}],"concepts":[{"id":"https://openalex.org/C2778384471","wikidata":"https://www.wikidata.org/wiki/Q417765","display_name":"Pioglitazone","level":4,"score":0.984403133392334},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9149143099784851},{"id":"https://openalex.org/C2780152017","wikidata":"https://www.wikidata.org/wiki/Q424771","display_name":"Rosiglitazone","level":3,"score":0.854786217212677},{"id":"https://openalex.org/C2776923340","wikidata":"https://www.wikidata.org/wiki/Q1393556","display_name":"Thiazolidinedione","level":4,"score":0.6133869290351868},{"id":"https://openalex.org/C2778150266","wikidata":"https://www.wikidata.org/wiki/Q7844989","display_name":"Troglitazone","level":4,"score":0.5987688899040222},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.556492805480957},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5532474517822266},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.5459796190261841},{"id":"https://openalex.org/C2778270857","wikidata":"https://www.wikidata.org/wiki/Q2723972","display_name":"Lipid profile","level":3,"score":0.4896274209022522},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4693544805049896},{"id":"https://openalex.org/C2778198053","wikidata":"https://www.wikidata.org/wiki/Q181754","display_name":"Heart failure","level":2,"score":0.46130305528640747},{"id":"https://openalex.org/C3018359032","wikidata":"https://www.wikidata.org/wiki/Q1550789","display_name":"Safety profile","level":3,"score":0.4221823811531067},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.3348315358161926},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.32251766324043274},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.32010915875434875},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.23947978019714355},{"id":"https://openalex.org/C187345961","wikidata":"https://www.wikidata.org/wiki/Q419629","display_name":"Peroxisome proliferator-activated receptor","level":3,"score":0.1036464273929596},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000077205","descriptor_name":"Pioglitazone","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D012307","descriptor_name":"Risk Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045162","descriptor_name":"Thiazolidinediones","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D045162","descriptor_name":"Thiazolidinediones","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D045162","descriptor_name":"Thiazolidinediones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1517/14740331003623218","doi":"https://doi.org/10.1517/14740331003623218","is_oa":false,"landing_page_url":"https://doi.org/10.1517/14740331003623218","pdf_url":null,"source":{"id":"https://openalex.org/S20709540","display_name":"Expert Opinion on Drug Safety","issn_l":"1474-0338","issn":["1474-0338","1744-764X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Drug Safety","raw_type":"journal-article"},{"id":"pmid:20175701","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20175701","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert opinion on drug safety","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":38,"referenced_works":["https://openalex.org/W71678318","https://openalex.org/W164912637","https://openalex.org/W1523312932","https://openalex.org/W1549782045","https://openalex.org/W1596678070","https://openalex.org/W1966062157","https://openalex.org/W1979820286","https://openalex.org/W1982311681","https://openalex.org/W1983864692","https://openalex.org/W1988492825","https://openalex.org/W1999225509","https://openalex.org/W2007939688","https://openalex.org/W2046218459","https://openalex.org/W2055119720","https://openalex.org/W2062560800","https://openalex.org/W2065619484","https://openalex.org/W2066708831","https://openalex.org/W2072661042","https://openalex.org/W2076669023","https://openalex.org/W2083719627","https://openalex.org/W2088127193","https://openalex.org/W2099673402","https://openalex.org/W2102675827","https://openalex.org/W2103156933","https://openalex.org/W2105719905","https://openalex.org/W2106603497","https://openalex.org/W2110102664","https://openalex.org/W2111951337","https://openalex.org/W2117938858","https://openalex.org/W2124401814","https://openalex.org/W2151490108","https://openalex.org/W2154580171","https://openalex.org/W2160433381","https://openalex.org/W2166179667","https://openalex.org/W2169881063","https://openalex.org/W2316193238","https://openalex.org/W2626017884","https://openalex.org/W3215022571"],"related_works":["https://openalex.org/W1994220341","https://openalex.org/W3029800468","https://openalex.org/W2028316975","https://openalex.org/W2120310114","https://openalex.org/W2037012816","https://openalex.org/W2793549302","https://openalex.org/W2107966736","https://openalex.org/W4283156641","https://openalex.org/W1997490166","https://openalex.org/W2080532505"],"abstract_inverted_index":{"IMPORTANCE":[0],"OF":[1],"THE":[2,135],"FIELD:":[3],"Thiazolidinediones":[4],"(TZDs)":[5],"are":[6,164,217],"useful":[7,203],"glucose-lowering":[8],"agents":[9],"for":[10,91,205],"patients":[11,210],"with":[12,40,78,102,162,211],"Type":[13,212],"2":[14,213],"diabetes.":[15,214],"Through":[16],"PPAR-gamma-mediated":[17],"effects,":[18],"these":[19],"drugs":[20],"not":[21,50],"only":[22],"improve":[23,43],"insulin":[24],"sensitivity":[25],"and":[26,36,177,200],"glycemia,":[27],"they":[28],"also":[29],"have":[30],"beneficial":[31],"effects":[32,160],"on":[33,147],"lipid":[34],"metabolism":[35],"the":[37,95,122,128,143,148,168,193,206],"vascular":[38],"endothelium,":[39],"potential":[41],"to":[42,75,99,126,167,219],"cardiovascular":[44,83,222],"risk.":[45],"However,":[46],"this":[47],"promise":[48],"has":[49,70],"been":[51,71],"entirely":[52],"fulfilled.":[53],"The":[54,66,87,157],"first":[55],"TZD,":[56,68],"troglitazone,":[57],"was":[58],"withdrawn":[59],"after":[60],"reports":[61],"of":[62,82,132,142,152,179,196,208],"severe":[63],"liver":[64],"damage.":[65],"second":[67],"rosiglitazone,":[69],"reported":[72,161],"in":[73,94,106,119,183,189],"meta-analyses":[74],"be":[76,100],"associated":[77,101],"possible":[79],"increased":[80],"risk":[81],"disease":[84],"(CVD)":[85],"events.":[86],"third":[88],"TZD":[89,169],"approved":[90],"clinical":[92],"use":[93],"US,":[96],"pioglitazone,":[97],"appears":[98],"decreased":[103],"CVD":[104],"events":[105],"most":[107],"studies/meta-analyses.":[108],"AREAS":[109],"COVERED":[110],"IN":[111],"THIS":[112],"REVIEW:":[113],"We":[114],"undertook":[115],"a":[116,202],"literature":[117],"search":[118],"Pubmed":[120],"from":[121],"year":[123],"2000":[124],"onwards":[125],"review":[127],"side":[129,149],"effect/safety":[130,150],"profile":[131,151,195],"pioglitazone.":[133,153],"WHAT":[134],"READER":[136],"WILL":[137],"GAIN:":[138],"A":[139],"comprehensive":[140],"summary":[141],"currently":[144],"available":[145],"data":[146],"TAKE":[154],"HOME":[155],"MESSAGE:":[156],"main":[158],"adverse":[159],"pioglitazone":[163,197],"those":[165],"common":[166],"class:":[170],"weight":[171],"gain,":[172],"pedal":[173],"edema,":[174],"bone":[175],"loss":[176],"precipitation":[178],"congestive":[180],"heart":[181],"failure":[182],"at-risk":[184],"individuals,":[185],"without":[186],"any":[187],"increase":[188],"CVD/all-cause":[190],"mortality.":[191],"Overall,":[192],"safety":[194],"is":[198],"favorable":[199],"remains":[201],"option":[204],"treatment":[207],"insulin-resistant":[209],"Further":[215],"studies":[216],"needed":[218],"confirm/clarify":[220],"its":[221],"benefits.":[223]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2017505271","counts_by_year":[{"year":2026,"cited_by_count":17},{"year":2025,"cited_by_count":20},{"year":2024,"cited_by_count":13},{"year":2023,"cited_by_count":13},{"year":2022,"cited_by_count":17},{"year":2021,"cited_by_count":10},{"year":2020,"cited_by_count":17},{"year":2019,"cited_by_count":10},{"year":2018,"cited_by_count":8},{"year":2017,"cited_by_count":14},{"year":2016,"cited_by_count":9},{"year":2015,"cited_by_count":10},{"year":2014,"cited_by_count":17},{"year":2013,"cited_by_count":14},{"year":2012,"cited_by_count":21}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
